Confronted with the health crisis related to the propagation of the Covid-19, the Group has joined the “Health Innovation Coalition – Health Crisis”. This coalition, which unites public and private health care stakeholders in France, has been set up to contribute to relieving congestion in the health system and ensuring patients with chronic diseases continue to be treated.
The most fragile people, notably those with chronic diseases (cancer, diabetes, COPD, asthma, heart failure, etc.) are particularly at risk in this context where the congestion of the health system may jeopardize the continuity of their treatment.
The objective of the “Health Innovation Coalition – Health Crisis” is to ensure the development and the implementation of innovative solutions in the health care sector on the basis of the needs identified and communicated by the health care establishments, health care professionals, and patient associations.
Concretely, calls for thematic projects have been launched to quickly identify project leaders, start-ups, French SMEs and mid-sized companies capable of deploying concrete solutions (information, home-based care, patient follow-up, medical treatment etc.). These calls for projects are operated by Digital Pharma Lab (DPL) via a platform available from March 25th to accompany, financially support, and deploy the solutions selected: https://www.coalitioncovid.org
The Health Innovation Coalition is initiated by France Biotech, France Digitale, MedTech in France, and AstraZeneca, with the participation and endorsement of the Public Hospitals of Paris (AP-HP) and France Assos Santé, the support of Bpifrance and EIT Health. As the Servier Group, numerous stakeholders committed themselves to supporting this initiative. Among these, the LEEM, Sanofi, Servier, Ipsen, Novartis, UCB, Amgen, Takeda, Chugai and GSK.
The coalition’s call for project remains open to all stakeholders who may give their support to this mission.